Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Core Insights - Phio Pharmaceuticals Corp. announced promising pathologic results from its ongoing Phase 1b trial for PH-762, showing 100% tumor clearance in one patient, over 90% in another, and over 50% in a third patient with cutaneous squamous cell carcinoma (cSCC) [2][3] - The trial has treated a total of 18 patients with cutaneous carcinomas, with cumulative results indicating six complete responses, two near complete responses, and two partial responses [3] - The Safety Monitoring Committee confirmed no dose-limiting toxicities or clinically relevant adverse effects at the maximum dose concentration, indicating a favorable safety profile for PH-762 [6][7] Company Overview - Phio Pharmaceuticals is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology aimed at treating various forms of skin cancer [9] - The lead clinical program, PH-762, targets the PD-1 gene and is being evaluated for its potential as a non-surgical treatment for skin cancers, including cSCC, melanoma, and Merkel cell carcinoma [9] Trial Design and Results - The Phase 1b trial is designed to assess the safety and tolerability of intratumoral PH-762 in patients with Stages 1, 2, and 4 cSCC, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma, with pathologic responses evaluated approximately five weeks post-injection [4] - The trial has shown no clinical progression of disease in any patients treated thus far, and additional patients may continue to be screened and treated as part of the fifth cohort [3][5]